At the base of the activities of the Vialli and Mauro Foundation for Research and Sport is the desire to operate concretely and to always be transparent. For this reason, in this section we intend to give you the possibility of knowing in detail and seeing how the dispersed funds will be used.
OBJECTIVE No. 1 (2005): PURCHASE OF A DIGITAL MAMMOGRAPH FOR THE HOSPITAL OF CANDIOLO
Today, the mammogram is still, despite its limits, the technology of excellence for the discovery of small dimension mammary carcinoma. This is not only in relation to the simplicity of execution and contained costs, but also due to the recent transformation of the same analogue technology (traditional) into digital technology. For additional information, click here.
OBJECTIVE No. 2 (2005 - 2006): FINANCE A RESEARCH PROJECT FOR ALS
Research conducted personally by Dr. Letizia Mazzini (Neurological Clinic - Amedeo Avogadro University of Piedmont Orientale - Novara), that will have the possibility of following the course of patients afflicted with Amyotrophic Lateral Sclerosis and surgical interventions.
To develop the research guidelines provided in the study, it requires a completely dedicated researcher available at the University of Novara for a period of at least five years. The forecasted gross cost is 30,000.00 Euro per year for a total of 150,000.00 Euro.
Corporate support
Target achieved The first scientific study regarding the Stem Cell research in Amyotrophic Lateral Sclerosis as been published
"Stem cell treatment in
Amyotrophic Lateral Sclerosis"
Journal of the
Neurological Sciences (2007)
Objective for 2005-2006 –PHASE 1 CLINICAL STUDY "CLINICAL APPLICATION OF AUTOLOGOUS MESENCHYMAL STEM CELLS IN AMIOTROFIC LATERAL SCLEROSIS"
Author: Dr. Letizia Mazzini, Department of Neurology, Easter Piedmont University, Novara (June 2008)
Scholarship extension letter::
OBJECT: Scholarship for project: CLINICAL STUDY IN PHASE 1 "Clinical application of autologous mesenchymal stem cells in amiotrofic lateral sclerosis"
OBJECTIVE No. 3 (2006): ACQUISITION REQUEST FOR AN INSTRUMENT FOR THE LABORATORY OF THE STEM CELL TRANSPLANT AND
CELLULAR THERAPY CENTRE
Studies are in progress in the Stem Cell Transplant Laboratory of the Regina Margherita Hospital of Turin regarding the mesenchymal stem cells (MSC). The MSC are drawn from a healthy individual and cultivated in a laboratory to be able to transplant them in diseased subjects for therapeutic purposes. In this case, the human MSC are isolated and expanded, originating from the medulla ossium (bone marrow) and driven to differentiation in a neutral sense in vitro.
The differentiation of the MSC into neutral cells is studied by means of biological cellular, molecular and electrophysiological techniques. In particular, the MSC placed in culture with diverse agents of differentiation including ß-mercaptoethanol; dimethyl sulfoxide + ß-hydroxyanisole; trans-retinoic acid and Neural Progenitor Maintenance Medium are able to modify their morphology (assuming a semi-neural aspect), express neural markers (including Nestin, Neuron-Specific Enolase; the antigen Neuronal Nuclear, the type 2 Microtubule-associated Protein and the Glial Fribrillary Acidic Protein) and present currents associated to the K+ channels raised by means of electrophysiological techniques. These cells (MSC) are able to excrete substances which favour the growth of the neurons and their prolongation.
Moreover, to study the capacity of the MSC to slow the progression of the neuronal damage and the eventual regeneration of the damaged nerve tissue, in the Human Anatomy and Legal Medicine laboratory of the University of Studies in Turin, directed by Prof. Alessandro Vercelli, in vivo studies are in progress on an experimental model of amyotrophic lateral sclerosis in mice. As a model, SOD-1 mice are used, that is a carrier of the mutated gene of the superoxide-dimutase of type 1. Such mutation provokes in mice a clinical picture similar to that of the patients afflicted with the familial form of Amyotrophic Lateral Sclerosis, a disease characterised by the progressive degeneration of motoneurons with consequent atrophy and muscular paralysis. The human MSC are marked with a nuclear colorant (Bisbenzimide) and inoculated in the spinal cord level. The results obtained to date demonstrate how the MSC inoculated at a spinal cord level of these mice are able to root, migrate, and survive in the long term and reduce the reactive astrogliosis, slowing the progression of the pathology. Such results reflect from a functional point of view in the improvement in the behavioural tests, therefore, in the motor functions in the transplanted mice. It is our intention to use the MSC to administer substances that prevent the neuronal death in the spinal cord location.
To continue such studies, the use of new instruments are deemed necessary including a laminar flow hood for the manipulation of cellular cultures with UV lamp and empty tap and a large capacity centrifuge counter ventilated for the isolation and expansion of the mesenchymal stem cells.
Project Manager:
Dr. Franca Fagioli
STEM CELL TRANSPLANT AND CELLULAR THERAPY CENTRE
University of Studies of Turin
Regina Margherita Hospital
Piazza Polonia, 94 – Turin
24/08/06- Thermo Electron Corporation's confirmation order:
Price reserved for us 11,266.00 Euro
code 82024100: Maxi Safe 2010 1.8/ with divided work station
code 52270240: UV Lamp with timer
Price reserved for us 4,785.00 Euro
code 11177560: Centrifuge C4i
code 11175338: M4 oscillating rotor
code 11174218: Set 4 vial racks
code 11174529: Set 4 adaptors
Price reserved for us 5,258.40 Euro
code 19371: Incubator + 8 door Kit
Total order in Euro 21,309.40 + vat 20%= Euro 25,571.28.
23/03/2008 Equipment installed and tested at the Centro Trapianti – Transplant Centre located in Piazza Polonia 94 – Turin
(Picture 1 -
Picture 2 -
Picture 3)
10/01/2007: Downpayment of € 6392.82 for equipment (invoice n. d/2 06 00 2508 Thermo Fisher Scientific)
15/07/2008:
Paid balance of € 19178.46 for equipment (invoice. n. d/2 06 00 2508 Thermo Fisher Scientific)
Raised Funds:25.571,28 €
Overall cost:25.571,28 €
OBJECTIVE No. 4 (2006 - 2010): FINANCE RESEARCH TO IDENTIFY THE GENETIC AND ENVIRONMENTAL RISK FACTORS OF ALS DEVELOPMENT IN FOOTBALL PLAYERS AND TO IDENTIFY POSSIBL MOLECULAR TARGETS FOR NEW THERAPY
A recent epidemiologic study on professional Italian football players engaged in series A and B between 1970 and 2001 showed how the frequency of ALS is significantly higher (approximately 6.5 times) and the age of onset is net inferior (on average 43 years) with respect to the occurrence in the general Italian population. (Brain Article). The origin of such increase and precocity is unknown.
It is possible to hypothesise, beyond the intense physical activity typical of an agonistic sport, that the increase in frequency is correlated to the use of substances assumed for the improvement in athletic performance and/or the use of pharmaceuticals for a prolonged period or in greater quantities with respect to the indicated therapeutic use. It is also assumable that there is a correlation with the specific traumas related to the game of football (for example, the headshot) or the prolonged exposure to toxins such as fertilisers and herbicides used on the football fields.
The fact that despite all of the football players examined being exposed to the same or similar environmental risk factors and only some of them contracted ALS indicates that the genetic characteristics that predispose some individuals to develop the disease probably exist. Therefore, to deepen the awareness regarding possible environmental factors and to identify the predisposed genes may provide very useful elements to identifying the origin of the disease in the 4000 Italian patients that are not professional football players.
The principal objectives are therefore, those of researching the bio-molecular characteristics that can define the increase in risk of developing ALS in professional football players and by means of these characteristics, identifying possible diagnostic indicators of the disease and possible targets for the development of new strategic therapies.
The study is pre-established to 1) investigate the clinical characteristics of Italian football players afflicted with ALS by retrospective and prospective analysis of all of the cases noted from 1970; 2) identify eventual genetic polymorphisms (polymorphisms) as possible risk factors for the development of the disease in professional football players; 3) develop cellular models obtained from peripheral tissues (e.g. primary lymphocyte and fibroblast cultures) (cellular cultures) with which it is possible to investigate mechanisms involved in the process of neurodegeneration; 4) identify by means of proteome analysis (proteome analysis) new biochemical indicators that are characteristic of the disease.
This study was created by the consolidated collaboration between Dr. Gabriele Mora of the Salvatore Maugeri Foundation in Pavia and Prof. Adriano Chiò of the Department of Neuroscience in Turin who were the authors of the survey on ALS in football players, along with the basic scientific contributions by Dr. Caterina Bendotti of the Department of Neuroscience at the “Mario Negri” Institute who has worked in this area for numerous years.
The overall cost of this study amounts to 220,000 Euro and includes 3 biennial scholarships, the necessary reactants for conducting the experiment and the acquisition of an instrument (Bio-Plex System, Bio-Rad). (Bioplex)
This study's overall cost amounts to 220,000 Euros covering
the costs of 3 two-year study grants, the reagents needed for experiments as well as the purchase of equipment (Bio-Plex System, Bio-Rad).
(Bioplex)
Open positions:
Human Resources
1 three-year study grant for biologist position at the Mario Negri Institute (cost 45.000 €)
1 two-year study grant for biologist position at the Maugeri Foundation (cost 40.000 €)
1 two-year study grant for biologist position at the Neuroscience Department of Turin (cost 40.000€)
Materials and equipment:
Bio-plex System (Bio-rad): system for the simultaneous detection of different
analytes (cytokines,Phospho-proteins, cell death factors).
Cost 72.000 € approximately.
15/07/2008: 40,000 Euros paid out for the Study grant at the Neuroscience Department of Turin University
15/09/2009: 40,000 Euros paid to Aisla onlus to fund the study grant at the Fondazione S.Maugeri of Milan
Project managers:
This project stems from the long-standing cooperation established among three researchers who have been working in the field of ALS clinical practice and research for years.
HIGH TECH COMMUNICATION DEVICES"If you want to understand how it feels like to be communication impaired, just go to any meeting and pretend you cannot speak.
You can use your hands but not pencil and paper, because these are tools that severely disabled, verbally impaired people cannot use. You'll be surrounded by people speaking in front of you, around you, below you, through you, or even for you, but they won't speak with you. You'll be ignored, and in the end it will just feel like being a piece of furniture".
Mario Melazzini, ALS patient
Augmentative and alternative communication systems
have been used for years to enable communication for Amyotrophic Lateral Sclerosis (ALS) patients,
even in the most advanced stages of the disease, when only little residual movements are retained, often in one body area alone.
Such systems are based on a hardware writing devices, often a laptop fitted with a special software,
and they mostly work based on letter scanning methods. This way, they can be controlled with a single switch through residual body movements, as long as these are retained.
In the late stages of the disease eye movements are often the only means that is left to a patient to
maintain connections with the surrounding environment, though he or she is still aware and eager to communicate,
to ask questions on the disease, discuss treatment options with his/her doctor, to tell family members or friends that he/she loves them,
and to socialize by exchanging thoughts and opinions with other people.
In such extreme scenarios, technology nowadays can do a great deal to enable patients to stay connected with the world around them.
Eye-controlled communication devices were designed expressly for that purpose; thanks to a videocamera connected to a pc and a software,
they enable patients to write, surf the internet, read and send e-mails, operate lighting and household equipment, and much more.
Leading-edge high tech communication equipment are fitted with a high resolution videocamera that tracks pupils'
movements in real time, and through the software, they detect which screen area is being looked at with outstanding accuracy.
When used in combination with a virtual keyboard, eye-controlled devices deliver excellent results: to write, patients just need to be able to look at letters on the screen.
Such devices are currently available in a price range from 20,000 to 24,000 Euros.
Cheaper but less accurate and reliable versions are now being marketed for about 7000-8000 Euros.
The technical features of the above-described systems are listed hereunder:
Remote, binocular eye-tracking system, with head movement tolerance, quick self-calibration –less
than 1.5 minutes-data recording capability, self calibrating when in use. The system is also equipped with a communication software suite to send/receive e-mails
(including, if needed, JPG attachment management), surf the net, make VoIP phone calls if combined with a TTS –text to speech- system and a video keyboard,
manage an image/text archive through an easy-to-use file manager, a visual agenda (that is including pictures) to store and manage contacts,
and an easy-to –use text reader for txt files. All of the applications listed are fitted with a simple, intuitive user interface and can be
controlled simply using the eyes (eye movements).
The system must also be equipped with a set of eye-controlled virtual keyboards -that is, interfacing with the eye-tracker - an integrated voice synthesizer
and a customized phone/mail account.
Taking into account the special physical needs of the patient, as well as with a view to a more timely system
customization and calibration, a procedure for remote technical assistance for changing the entire set of working parameters must also be envisaged.
THE "VIALLI E MAURO" FOUNDATION /AISLA ONLUS JOINT PROJECT
To date, with huge financial efforts Aisla Onlus has already given 13 "I Able My Tobii" communication devices on a free loan for use to patients who urgently needed them.
Moreover, thanks to the work done by Aisla jointly with the Ministry for Health, the Conferenza Stato-Regioni (Italian Conference of State and Regions)
has recently approved the allocation of a further 10 million Euros, to be distributed among Italian regions for the purchase of more high tech communication devices for ALS patients.
AISLA onlus intends to buy another 10 communication devices available on a free loan for use,
5 of which will be bought with a contribution from the Fondazione Vialli e Mauro onlus.
OBJECTIVE No. 6 (2008): PURCHASE AN ELECTROMYOGRAPH TO BE DONATED TO
THE NEMO CLINICAL CENTRE OF MILAN, AT THE NIGUARDA HOSPITAL CENTRE
The electromyograph is an equipment that identifies, stores and process the electrical signals associated with the muscular activity of any kind and area of the human body.
Thanks to this equipment it is possible, for patients suffering from neuromuscular disorders, particularly for the Amiotrofic Lateral Sclerosis, to identify the suffering signs of the II motoneuron through the study of the peripheral nervous system and recording of the muscular electrical activity, by allowing the clinical neurologist to add an important element in reaching the certain diagnosis of the disorder.
In particular, electromyography is useful for:
• localising the disorder;
• identifying the underlying pathological process;
• characterising the deficiency;
• assessing the seriousness of the deficiency;
• monitoring the course of the disease;
• assessing the efficacy of the possible adopted therapies.
The total cost of this equipment will be about 50,000 Euro, and its use is fort the Centro Clinico Nemo di Milano, presso l'Azienda Ospedaliera Niguarda (Nemo Clinical Centre of Milan, at the Niguarda Hospital Centre). This Centre was established and wished thanks to the cooperation and tenaciousness between AISLA and UILDM, and created for the diagnosis and care of neuromuscular disorders. It is the first concrete model of subsidiarity, with the real aim of ensuring the patient's overall treatment.
OBJECTIVE No. 7 (2008): FINANCING OF A BUDGET FOR ONE POSITION
AS NEUROLOGY UNIVERSITY RESEARCHER FOR THE FACILITY OF MEDICINE AND SURGERY OF THE UNIVERSITY
OF TURIN ON THE AMIOTROFIC LATERAL SCLEROSIS
The amiotrofic lateral sclerosis (ALS) is a degenerative disease of the nervous system, with selective involvement of motoneurons I and II, still considered rare affecting both men (with slight prevalence) and women, of all ages, but mostly in the seventh decade of life, determining a progressive deficiency of the motor functions at spinal (atrophy, cramps, fasciculation, plasticity and loss of muscular strength in the 4 limbs), respiratory (with involvement of the diaphragm and intercostals muscles) and bulbar (that is, the muscles innervated by cranial nerves causing dysphonia, dysartria and dysphagia) level.
The disease has an average survival of about 3-4 years from the onset of the symptoms and the death occurs for respiratory insufficiency due to pneumonia, often “ab ingestis” (for ingestion of food in the respiratory tract) or to a progressive deficiency of the respiratory muscles.
According to the data of the Piedmont and Valle d’Aosta Registry for ALS, this disease has an incidence of about 2.9 cases per 100,000 inhabitants (equal to about 120 new cases every year in Piedmont and Valle d’Aosta) and a prevalence of about 7.4 cases for 100,000 inhabitants (equal to about 320 patients every year).
The cause is still unknown and there are no aetiological therapies, except for the riluzole, which has however shown its efficiency only in slowing the progression of the disease. Nevertheless, there are efficient symptomatic therapies and the possibility to assist properly the patient affected by ALS, but the patient must be fully assisted by specialised centres.
In the last years, the activity of the ALS Centre of Turin of the I Neurological Clinic of the University of Turin, managed by Prof. Roberto Mutani, and under the direction of Prof. Adriano Chiò, has grown exponentially in the quantity of work and diversification of objectives. Since its establishment, assistance and clinical research have been its main objectives:
a) the number of scientific publications has grown constantly, with a very high and top quality productivity; in addition, the number of scientific contributions presented in the most important international as well as national conferences is very high;
b) currently, several internal research projects are in progress, with collaborations inside the interdisciplinary research group (Turin ALS Research Group), and with external collaborations (Italian study group on ALS, EURALS, NIH and other collaborations); in particular, studies of molecular genetics and wide genomic screening; clinical and epidemiological studies (population perspective register, risk factors, such as sport, in particular football, studies on the evaluation of stress and traumas, on the weight, lipid profile); clinical studies of evaluation of the respiratory and diet parameters; psychological clinical studies on the quality of life and neuropsychological; research studies of diagnosis and prognosis markers; neurophysiologic studies); experimental clinical studies (see point d).
c) the number of outpatients and, first in Italy, treated at home with an institutionalised service of home specialist assistance, is increasingly growing, with ever more frequent admissions from outside the Region, reaching about 650 outpatient visits every year and about 200 home visits; in addition, the admissions in this structure for diagnostic and therapeutic purposes and for the execution of procedures such as the percutaneous radiological gastrostomy (proven by this group, first in the world, to be the best for patients affected by ALS) cover a large part of the assistance activity;
d) currently, 6 therapeutic trials are in progress, two international and four domestic, of which three spontaneous studies: STEMALS multi-centre study, which evaluates the use of growth factors for the mobilisation of mesenchymal stem cells; SIRONA ONO2506PO protocol; ALALS Protocol; GOALS protocol; LITALS protocol; LAC protocol.
This quantity of work, requiring specialist training, is currently carried out by Prof. Adriano Chiò and his collaborators who constantly and specifically work on this disease, who cover non-structured working positions (2 research graduate students, 3 postgraduate students, 2 psychologists under contract, 1 scholarship biologist, some students writing a graduation thesis). It therefore seems necessary to increase the staff, structured in such a manner to ascertain the execution of the assistance activities, but also and particularly, on the research for such a devastating disease such as ALS.
Raised Funds:450.000,00 €
Overall cost:450.000,00 €
OBJECTIVE No. 8 (2008): ARISLA, RESEARCH AGENCY FOR AMIOTROFIC LATERAL SCLEROSIS (ALS)
AriSLA
Research Agency for Amiotrofic Lateral Sclerosis
The mission: operate as catalyser of basic, clinical, and technological research by creating the most suitable synergies to offer ALS patients increased hopes of cure and improved quality of their life.
19.12.08 Ribbon cutting ceremony for the AriSLA seat, Research Agency for Amiotrofic Lateral Sclerosis
A few months after the end of the assessment of the projects submitted for the Research Grant call for
proposals 2009, AriSLA issued its second call for
ALS research project proposals:
on the 30th of June, 2010 the Foundation will officially open the:
CALL FOR PROPOSALS OF RESEARCH PROJECTS ON ALS -2010
With this new call for proposals AriSLA keeps pursuing its mission by promoting the new approaches of research to the struggle against
ALS, with a view to enhance the impact and effectiveness of investments into research and speed up their application in clinical practice,
thus offering ALS patients more hopes for a cure, better living conditions and life expectancy.
The deadline for submission of Project Proposals is 15 September 2010, 1.00 pm..
December 2008:
Advance payment paid € 50.00,00
May 2009:
Extra donation to support the start-up of the AriSLA Foundation approved and paid:
OBJECTIVE NR. 09 (2010): AWARD OF A SCHOLARSHIP FOR A TELETHON RESEARCHER
During Telethon 2009 (tv marathon) the Fondazione committed to funding a study grant of 30,000 Euros for the research project on
"New biomarkers for Amyotrophic Lateral Sclerosis, their Role in Disease Pathogenesis and Possible Targets for Therapy".
The project, carried out by Dr.Valentina Bonetto, researcher at the Telethon Dulbecco Institute, aims to develop new and innovative approaches to therapy.
Such studies have identified a number of proteins that appear to be involved in the process leading to motor neurons death,
which is why their study is now opportune with a view to their use as targets for therapy due to their specificity in diagnosing ALS accurately.
It is an organization working the whole year to raise funds in order to finance research projects on rare genetic diseases. It is a team of cutting-edge scientists that have distinguished themselves in Italy and all over the world for the quality of their work.
It is a transparent institution guaranteeing that donations are used in the best way. All this is Telethon. It was established in 1990 upon initiative of a group of mothers, whose children were affected by muscular dystrophy. Since 1992 the Telethon Committee has decided to use its funds for research activities on all genetic diseases.
Founded by Susanna Agnelli, every year it reaches the Italian families thanks to the television marathon, which in December 2009 celebrated its 20th edition. Since 2009 it has been chaired by Luca Cordero di Montezemolo.
For further information:
http://www.telethon.it
OBJECTIVE NR. 10 (2010):
TAKE YOUR STAND IN THE BATTLE AGAINST ALS!
In June 2009, AriSLA launched its first Call for Ideas 2009 call for research proposals in order to offer researchers the possibility to support quality research projects that can significantly contribute to further investigate on ALS possible causes and treatment solutions.
Following an in-depth selection stage based on the peer review principle, the Arisla International Scientific Committee identified five A-level projects out of 105 projects submitted. Therefore a total of 1,508,800 euro was resolved and allocated for these research projects:
Thanks to the awareness-raising campaign started through the solidarity SMS campaign carried out from 31 January to 21 February 2010, the Vialli and Mauro Foundation collected 48.752,00 euro that were granted to the project that ranked first in the call for research proposals: “CanALS: A Randomized, Double-Blind, Placebo-Controlled, Multicentre Study of Asses the Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neurone Disease Patiens.”
OBIETTIVO NR. 11 (2011):
ADOTTARE IL PROGETTO DI RICERCA EPOSS
On 30 June 2010, a few months after assessing the projects submitted in relation to the 2009 Tender, AriSLA published its second Call for tenders named ”Concorso per Progetti di Ricerca sulla SLA 2010" (Tender for ALS Research Projects for 2010).
Within the biomedical research area, the 2010 AriSLA Tender envisages the submittal of two types of research projects: Full grant and Pilot grant[1], focused on basic and translational research. In this way AriSLA wishes to focus on research relating to the pathogenesis and the causes of the disease.
The Vialli and Mauro Foundation decided to adopt one of the five Full Grant projects that the International Internal Committee for scientific excellence deemed worthy of note. The project, named EPOSS, will last 18 months and amounts to 223,000 euro.
223,000 EURO COLLECTED THANKS TO SLANCIO DI VITA FOOTBALL MATCH, 23 MARCH 2011 STADIO OLIMPICO DI TORINO, TURIN (photo of the cheque) (photo of the cheque)
Thanks to all the people who contributed to the event, inside and outside the stadium, the ambitious objective was reached!
The fundamental sponsoring of the Municipality of Turin and the participation of the two teams, Juventus and Torino historic football players, Partner companies, Artists who enriched the evening events, Volunteers, Suppliers and the whole staff have made this dream come true.
OBJECTIVE No. 12: (2011) CONTRIBUTION TO BUILD THE SECOND TOWER FOR CANCER RESEARCH AND TREATMENT OF THE CANDIOLO INSTITUTE
Following the 25th anniversary of Fondazione Piemontese per la Ricerca sul Cancro (Piedmont Foundation for Cancer Research), the Vialli and Mauro Foundation decided to earmark part of the profit from the 8th Pro-Am Vialli & Mauro Golf Cup for the Candiolo Institute. This contribution, equal to EUR 50,000, will be used to build the Second Tower for Research and Treatment, which will complement the original plant of the Candiolo Institute. This is the important aim that Fondazione Piemontese per la Ricerca sul Cancro will try reach by the following years.
The Second Tower for Research and Treatment will host the Interdisciplinary Cancer Centre where, thanks to a multidisciplinary integrated approach, the molecular mechanisms in the spreading and growth of metastasis will be investigated. The Interdisciplinary Cancer Centre is a project aimed at recreating the same revolution generated by the knowledge of human genome in oncology. Doctors, biologists, engineers, physicists, and maths and IT experts will give their contribution to the project. The project was designed in cooperation with a team of experts from authoritative European and American institutes and its importance was recognised by 42 Italian and foreign scientists.
EUR 50,000 RAISED DURING THE 8TH PRO-AM VIALLI & MAURO GOLF CUP - 5 SEPTEMBER 2011 'I ROVERI' ROYAL PARK OF FIANO TORINESE. (Photo of the contribution)- RECEIPT
(During the 8th Pro-Am Vialli & Mauro Golf Cup, EUR 150,000 were raised, of which EUR 50,000 were earmarked for Fondazione Piemontese per la Ricerca sul Cancro and EUR 100,000 were allocated to the annual contribution to AriSLA (Agenzia Italiana di Ricerca per la SLA), see objective no. 8)
Thanks to all those people who participated in the event and gave their contribution, we reached our objective!
OBJECTIVE NR. 13 (2011):
TAKE YOUR STAND IN THE BATTLE AGAINST ALS!
With the sms solidarity campaign 2011 (5 – 26 March) the Vialli and Mauro Foundation raised a total of 94.955,37 € that were allocated to one of the basic research project of the AriSLA Call for Ideas 2009:
"PRALS – P2X7 Receptor in Amyotrophic Lateral Sclerosis"
The basic research project aims to study the role of P2X7 receptor in neuro-inflammation, mediated by the activation of microglia, that is involved in the first and most active immune defense in the central nervous system. The project, which starts one year ago has already reached some goals. In particular, the P2X7 receptor has been silenced, that means its expression has been blocked in transgenic mice with the disease, to verify whether its removal is able to improve pathological conditions in the mouse models.
Principal Investigator: Nadia D'Ambrosi - Istituto di Neurobiologia e Medicina Molecolare, Consiglio Nazionale delle Ricerche (CNR)
Partner 1: Mauro Cozzolino - Fondazione Santa Lucia IRCCS, Roma
Partner 2: Patrizia Popoli - Istituto Superiore di Sanità, Roma
OBJECTIVE NR. NR. 14 (2011):
ADOPT ONE OF THE RESEARCH PROJECT OF THE ARISLA CALL FOR PROJECTS 2011
he proceeds of "EVEN YOUR STAR WILL LEAVE A WAKE…FOR RESEARCH" with the contribution of Nova Coop will be donated to one of the winner projects of the AriSLA Call for Projects 2011.
To the third 2011 Call 55 projects proposals have been submitted, 16 Full Grants* and 39 Pilot Grants**, for a total request of contribution of about 7 ml euros.
Funded projects have been chosen through a peer-review evaluation process. The peer review methodology guarantees the impartiality and transparency of the procedure, and thank to the work of the International Scientific Committee, 7 winner projects of excellence have been identified. The winner projects will be supported by AriSLA contribution of about 1.197.125 euros.
Will soon be announced the amount raised and the selected project.
English 
